The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study
Abstract Background Substance use disorders (SUD) often co-occur with attention deficit hyperactivity disorder (ADHD). Although the short-term effects of some specific interventions have been investigated in randomized clinical trials, little is known about the long-term clinical course of treatment...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-09-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12888-022-04259-6 |
| _version_ | 1811208676494540800 |
|---|---|
| author | Christoffer Brynte Myriam Aeschlimann Csaba Barta Alex Hendikus Abraham Begeman Amanda Bäcker Cleo Lina Crunelle Constanza Daigre Laura De Fuentes-Merillas Zsolt Demetrovics Geert Dom Lara Grau López Romain Icick Brian Johnson Peter Joostens Máté Kapitány-Fövény Emily Karsinti Falk Kiefer Maija Konstenius Frances R. Levin Mathias Luderer Wiebren Markus Frieda Matthys Franz Moggi Raul Felipe Palma-Alvarez Maria Paraskevopoulou J. Antoni Ramos-Quiroga Arnt Schellekens Leila M. Soravia Norman Therribout Anil Thomas Geurt van de Glind Michiel Willem van Kernebeek Sabine Vollstädt-Klein Florence Vorspan Wim van den Brink Johan Franck |
| author_facet | Christoffer Brynte Myriam Aeschlimann Csaba Barta Alex Hendikus Abraham Begeman Amanda Bäcker Cleo Lina Crunelle Constanza Daigre Laura De Fuentes-Merillas Zsolt Demetrovics Geert Dom Lara Grau López Romain Icick Brian Johnson Peter Joostens Máté Kapitány-Fövény Emily Karsinti Falk Kiefer Maija Konstenius Frances R. Levin Mathias Luderer Wiebren Markus Frieda Matthys Franz Moggi Raul Felipe Palma-Alvarez Maria Paraskevopoulou J. Antoni Ramos-Quiroga Arnt Schellekens Leila M. Soravia Norman Therribout Anil Thomas Geurt van de Glind Michiel Willem van Kernebeek Sabine Vollstädt-Klein Florence Vorspan Wim van den Brink Johan Franck |
| author_sort | Christoffer Brynte |
| collection | DOAJ |
| description | Abstract Background Substance use disorders (SUD) often co-occur with attention deficit hyperactivity disorder (ADHD). Although the short-term effects of some specific interventions have been investigated in randomized clinical trials, little is known about the long-term clinical course of treatment-seeking SUD patients with comorbid ADHD. Aims This paper presents the protocol and baseline clinical characteristics of the International Naturalistic Cohort Study of ADHD and SUD (INCAS) designed and conducted by the International Collaboration on ADHD and Substance Abuse (ICASA) foundation. The overall aim of INCAS is to investigate the treatment modalities provided to treatment-seeking SUD patients with comorbid ADHD, and to describe the clinical course and identify predictors for treatment outcomes. This ongoing study employs a multicentre observational prospective cohort design. Treatment-seeking adult SUD patients with comorbid ADHD are recruited, at 12 study sites in nine different countries. During the follow-up period of nine months, data is collected through patient files, interviews, and self-rating scales, targeting a broad range of cognitive and clinical symptom domains, at baseline, four weeks, three months and nine months. Results A clinically representative sample of 578 patients (137 females, 441 males) was enrolled during the recruitment period (June 2017-May 2021). At baseline, the sample had a mean age (SD) of 36.7 years (11.0); 47.5% were inpatients and 52.5% outpatients; The most prevalent SUDs were with alcohol 54.2%, stimulants 43.6%, cannabis 33.1%, and opioids 14.5%. Patients reported previous treatments for SUD in 71.1% and for ADHD in 56.9%. Other comorbid mental disorders were present in 61.4% of the sample: major depression 31.5%, post-traumatic stress disorder 12.1%, borderline personality disorder 10.2%. Conclusions The first baseline results of this international cohort study speak to its feasibility. Data show that many SUD patients with comorbid ADHD had never received treatment for their ADHD prior to enrolment in the study. Future reports on this study will identify the course and potential predictors for successful pharmaceutical and psychological treatment outcomes. Trial registration ISRCTN15998989 20/12/2019. |
| first_indexed | 2024-04-12T04:25:35Z |
| format | Article |
| id | doaj.art-4e31808ab99041f5ab3785ea796dfab2 |
| institution | Directory Open Access Journal |
| issn | 1471-244X |
| language | English |
| last_indexed | 2024-04-12T04:25:35Z |
| publishDate | 2022-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Psychiatry |
| spelling | doaj.art-4e31808ab99041f5ab3785ea796dfab22022-12-22T03:48:05ZengBMCBMC Psychiatry1471-244X2022-09-012211810.1186/s12888-022-04259-6The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS studyChristoffer Brynte0Myriam Aeschlimann1Csaba Barta2Alex Hendikus Abraham Begeman3Amanda Bäcker4Cleo Lina Crunelle5Constanza Daigre6Laura De Fuentes-Merillas7Zsolt Demetrovics8Geert Dom9Lara Grau López10Romain Icick11Brian Johnson12Peter Joostens13Máté Kapitány-Fövény14Emily Karsinti15Falk Kiefer16Maija Konstenius17Frances R. Levin18Mathias Luderer19Wiebren Markus20Frieda Matthys21Franz Moggi22Raul Felipe Palma-Alvarez23Maria Paraskevopoulou24J. Antoni Ramos-Quiroga25Arnt Schellekens26Leila M. Soravia27Norman Therribout28Anil Thomas29Geurt van de Glind30Michiel Willem van Kernebeek31Sabine Vollstädt-Klein32Florence Vorspan33Wim van den Brink34Johan Franck35Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care ServicesUniversity Hospital of Psychiatry and Psychotherapy, University of BernDepartment of Molecular Biology, Institute of Biochemistry and Molecular Biology, Semmelweis UniversityDe Hoop GgzDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care ServicesDepartment of Psychiatry, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis BrusselDepartment of Psychiatry, Addiction and Dual Diagnosis Section, Hospital Universitari Vall d’HebronNovadic-Kentron Addiction Care; Nijmegen Institute for Scientist Practitioners in AddictionInstitute of Psychology, ELTE Eötvös Loránd UniversityUniversity of AntwerpDepartment of Psychiatry, Addiction and Dual Diagnosis Section, Hospital Universitari Vall d’HebronUniversité de Paris CitéSUNY Upstate UniversityAlexianen Zorggroep TienenFaculty of Health Sciences, Semmelweis UniversityUniversité Paris-Nanterre, CliPsyD Laboratory FR and APHP, Fernand Widal Hospital, Universitary Department of Psychiatry and AddictologyDepartment of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, University of HeidelbergDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care ServicesVagelos College of Physicians and SurgeonsDepartment of Psychiatry, Psychosomatic Medicine and Psychoterapy, University Hospital Frankfurt, Goethe UniversityIriszorg Addiction Care, Nijmegen Institute for Scientist Practitioners in AddictionDepartment of Psychiatry, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis BrusselUniversity Hospital of Psychiatry, Translational Research Center, University of BernDepartment of Psychiatry, Addiction and Dual Diagnosis Section, Hospital Universitari Vall d’HebronDepartment of Psychiatry, RadboudumcDonders Institute for Brain, Cognition and BehaviorDepartment of Psychiatry, Addiction and Dual Diagnosis Section, Hospital Universitari Vall d’HebronDepartment of Psychiatry, RadboudumcDonders Institute for Brain, Cognition and BehaviorUniversity Hospital of Psychiatry, Translational Research Center, University of BernUniversité Paris-Nanterre, CliPsyD Laboratory FR and APHP, Fernand Widal Hospital, Universitary Department of Psychiatry and AddictologyMt. Sinai, Icahn School of MedicineUniversity of Applied Sciences-UtrechtDepartment of Psychiatry, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis BrusselDepartment of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, University of HeidelbergUniversité de Paris CitéAmsterdam University Medical Centers, Location Academic Medical CenterDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care ServicesAbstract Background Substance use disorders (SUD) often co-occur with attention deficit hyperactivity disorder (ADHD). Although the short-term effects of some specific interventions have been investigated in randomized clinical trials, little is known about the long-term clinical course of treatment-seeking SUD patients with comorbid ADHD. Aims This paper presents the protocol and baseline clinical characteristics of the International Naturalistic Cohort Study of ADHD and SUD (INCAS) designed and conducted by the International Collaboration on ADHD and Substance Abuse (ICASA) foundation. The overall aim of INCAS is to investigate the treatment modalities provided to treatment-seeking SUD patients with comorbid ADHD, and to describe the clinical course and identify predictors for treatment outcomes. This ongoing study employs a multicentre observational prospective cohort design. Treatment-seeking adult SUD patients with comorbid ADHD are recruited, at 12 study sites in nine different countries. During the follow-up period of nine months, data is collected through patient files, interviews, and self-rating scales, targeting a broad range of cognitive and clinical symptom domains, at baseline, four weeks, three months and nine months. Results A clinically representative sample of 578 patients (137 females, 441 males) was enrolled during the recruitment period (June 2017-May 2021). At baseline, the sample had a mean age (SD) of 36.7 years (11.0); 47.5% were inpatients and 52.5% outpatients; The most prevalent SUDs were with alcohol 54.2%, stimulants 43.6%, cannabis 33.1%, and opioids 14.5%. Patients reported previous treatments for SUD in 71.1% and for ADHD in 56.9%. Other comorbid mental disorders were present in 61.4% of the sample: major depression 31.5%, post-traumatic stress disorder 12.1%, borderline personality disorder 10.2%. Conclusions The first baseline results of this international cohort study speak to its feasibility. Data show that many SUD patients with comorbid ADHD had never received treatment for their ADHD prior to enrolment in the study. Future reports on this study will identify the course and potential predictors for successful pharmaceutical and psychological treatment outcomes. Trial registration ISRCTN15998989 20/12/2019.https://doi.org/10.1186/s12888-022-04259-6ADHDSUDComorbidity |
| spellingShingle | Christoffer Brynte Myriam Aeschlimann Csaba Barta Alex Hendikus Abraham Begeman Amanda Bäcker Cleo Lina Crunelle Constanza Daigre Laura De Fuentes-Merillas Zsolt Demetrovics Geert Dom Lara Grau López Romain Icick Brian Johnson Peter Joostens Máté Kapitány-Fövény Emily Karsinti Falk Kiefer Maija Konstenius Frances R. Levin Mathias Luderer Wiebren Markus Frieda Matthys Franz Moggi Raul Felipe Palma-Alvarez Maria Paraskevopoulou J. Antoni Ramos-Quiroga Arnt Schellekens Leila M. Soravia Norman Therribout Anil Thomas Geurt van de Glind Michiel Willem van Kernebeek Sabine Vollstädt-Klein Florence Vorspan Wim van den Brink Johan Franck The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study BMC Psychiatry ADHD SUD Comorbidity |
| title | The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study |
| title_full | The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study |
| title_fullStr | The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study |
| title_full_unstemmed | The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study |
| title_short | The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study |
| title_sort | clinical course of comorbid substance use disorder and attention deficit hyperactivity disorder protocol and clinical characteristics of the incas study |
| topic | ADHD SUD Comorbidity |
| url | https://doi.org/10.1186/s12888-022-04259-6 |
| work_keys_str_mv | AT christofferbrynte theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT myriamaeschlimann theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT csababarta theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT alexhendikusabrahambegeman theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT amandabacker theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT cleolinacrunelle theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT constanzadaigre theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT lauradefuentesmerillas theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT zsoltdemetrovics theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT geertdom theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT laragraulopez theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT romainicick theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT brianjohnson theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT peterjoostens theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT matekapitanyfoveny theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT emilykarsinti theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT falkkiefer theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT maijakonstenius theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT francesrlevin theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT mathiasluderer theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT wiebrenmarkus theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT friedamatthys theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT franzmoggi theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT raulfelipepalmaalvarez theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT mariaparaskevopoulou theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT jantoniramosquiroga theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT arntschellekens theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT leilamsoravia theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT normantherribout theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT anilthomas theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT geurtvandeglind theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT michielwillemvankernebeek theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT sabinevollstadtklein theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT florencevorspan theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT wimvandenbrink theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT johanfranck theclinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT christofferbrynte clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT myriamaeschlimann clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT csababarta clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT alexhendikusabrahambegeman clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT amandabacker clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT cleolinacrunelle clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT constanzadaigre clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT lauradefuentesmerillas clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT zsoltdemetrovics clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT geertdom clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT laragraulopez clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT romainicick clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT brianjohnson clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT peterjoostens clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT matekapitanyfoveny clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT emilykarsinti clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT falkkiefer clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT maijakonstenius clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT francesrlevin clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT mathiasluderer clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT wiebrenmarkus clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT friedamatthys clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT franzmoggi clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT raulfelipepalmaalvarez clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT mariaparaskevopoulou clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT jantoniramosquiroga clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT arntschellekens clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT leilamsoravia clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT normantherribout clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT anilthomas clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT geurtvandeglind clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT michielwillemvankernebeek clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT sabinevollstadtklein clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT florencevorspan clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT wimvandenbrink clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy AT johanfranck clinicalcourseofcomorbidsubstanceusedisorderandattentiondeficithyperactivitydisorderprotocolandclinicalcharacteristicsoftheincasstudy |